OBJECTIVE: This study was performed to evaluate the therapeutic effect of cisplatin-gemcitabine combination chemotherapy for advanced non-small cell lung cancer (NSCLC).
MATERIALS AND METHODS: Dataset GSE39345 from patients who underwent cisplatin-gemcitabine combination chemotherapy and normal controls was downloaded from Gene Expression Omnibus. Differentially expressed genes (DEGs) were identified using Limma package and divided into 3 datasets: unique DEGs in NSCLC before chemotherapy vs. control samples (dataset A), common DEGs (dataset B), unique DEGs in NSCLC after chemotherapy vs. control samples (dataset C). Enrichment analysis was to identify functions or pathways of DEGs. Protein-protein interaction (PPI) analysis was to identify hub nodes and interacting pairs in dataset C and constructed into PPI network using Cytoscape software, followed by screening of small molecules using Connectivity Map.
RESULTS: Herein, 230 unique DEGs in dataset A, 584 common DEGs in dataset B and 1562 unique DEGs in dataset C were obtained. The 230 DEGs were significantly enriched in methylation and positive regulation of cell differentiation; the 584 DEGs were significantly enriched in positive regulation of cell differentiation and cytokine-cytokine receptor interaction pathway; the 1562 DEGs were enriched in functions associated with defense response. RELA and PLCB3 correlated with PLCE1 and INADL were hub nodes in the PPI network. Cefoperazone was the small molecule negatively correlated with DEGs.
CONCLUSIONS: Chemotherapy could prevent genes from aberrant methylation, partially restore cell differentiation process, fail to regulate cytokine-cytokine receptor interaction and induce weakened defense response. Cefoperazone could be used as a supplementary drug.Free PDF Download
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
To cite this article
G.F. Ma, R.F. Zhang, K.J. Ying, D. Wang
Effect evaluation of cisplatin-gemcitabine combination chemotherapy for advanced non-small cell lung cancer patients using microarray data
Eur Rev Med Pharmacol Sci
Vol. 19 - N. 4